# A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer

> **NCT06023277** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Jacinto Convit World Organization Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **BIOLOGICAL:** ConvitVax

## Key facts

- **NCT ID:** NCT06023277
- **Lead sponsor:** Jacinto Convit World Organization Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2025-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-09-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06023277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06023277, "A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06023277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*